These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24363807)

  • 41. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer.
    Zhang L; Sun H; Du S; Xu W; Xin J; Guo Q
    Nucl Med Commun; 2018 Nov; 39(11):1045-1052. PubMed ID: 30204642
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer.
    Nair VS; Barnett PG; Ananth L; Gould MK;
    Chest; 2010 May; 137(5):1150-6. PubMed ID: 20038738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma.
    Toshida K; Itoh S; Iseda N; Izumi T; Yoshiya S; Toshima T; Ninomiya M; Iwasaki T; Oda Y; Yoshizumi T
    Cancer Sci; 2024 Jan; 115(1):170-183. PubMed ID: 37878531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Koizumi T; Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Mamiya K; Tateishi K; Katou A; Oguchi K
    Med Oncol; 2017 Sep; 34(10):169. PubMed ID: 28864950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
    J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer.
    Ko YH; Domingo-Vidal M; Roche M; Lin Z; Whitaker-Menezes D; Seifert E; Capparelli C; Tuluc M; Birbe RC; Tassone P; Curry JM; Navarro-Sabaté À; Manzano A; Bartrons R; Caro J; Martinez-Outschoorn U
    J Biol Chem; 2016 Dec; 291(51):26291-26303. PubMed ID: 27803158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
    Hong M; Xia Y; Zhu Y; Zhao HH; Zhu H; Xie Y; Fan L; Wang L; Miao KR; Yu H; Miao YQ; Wu W; Zhu HY; Chen YY; Xu W; Qian SX; Li JY
    Leuk Res; 2016 Nov; 50():72-77. PubMed ID: 27693855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.
    Wanka C; Steinbach JP; Rieger J
    J Biol Chem; 2012 Sep; 287(40):33436-46. PubMed ID: 22887998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
    Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
    Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
    Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
    Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Lau CL; Jones DR
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):43-8. PubMed ID: 19154901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.